Zantac MDL Moves Forward As Parties Select Cases for Bellwether Trials
On April 1, 2020, the Food and Drug Administration (FDA) requested manufacturers withdraw all prescription and over-the-counter ranitidine (Zantac) drugs from the market. This, after tests, showed the products could contain N-nitrosodimethylamine (NDMA), a potent carcinogen.
Meanwhile, many consumers had already filed Zantac lawsuits, claiming that they had taken the drug for years and were later diagnosed with cancer as a result. In February 2020, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all federally filed Zantac lawsuits in the U.S. District Court for the Southern District of Florida for consolidated pre-trial proceedings.
Now the judge overseeing the Zantac MDL has ordered the parties to randomly select 200 cases to be part of an initial discovery pool.
TriMark Legal Funding provides non-recourse pre-settlement and post-settlement funding to injured plaintiffs with multidistrict litigation cases nationwide. Call (877) 932-2628 to see if you qualify for funding.
This post originally appeared here: https://newyork.legalexaminer.com/legal/zantac-mdl-moves-forward-as-parties-select-cases-for-bellwether-trials/
Click here to see the full original article.